

Other Reviews - - Other Review

# MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT.

Code: PM40716955

Year: 2025 Date: 2018

Author: Chapman N

## Study design (if review, criteria of inclusion for studies)

Systematic review

## Participants

Studies about CF Newborn screening

## Interventions

Newborn screening

## Outcome measures

Cost-effectiveness

## Main results

Six health economic evaluations were found. Where included in the comparison, IRT/PAP consistently was the most cost-effective strategy in terms of cost per case detected or life years gained. However, some heterogeneity with respect to cut-off values used and the number of DNA mutations included in the screening strategies was observed, and the methodological quality differed considerably between studies.

## Authors' conclusions

The evidence suggested that (i) all screening strategies are cost-effective as compared to the no-screening option and (ii) IRT-PAP seems to be the most cost-effective screening strategy towards CFNBS. Methodological and contextual differences of the individual studies make it difficult to derive strong conclusions from this evidence. Nevertheless, from a health-economic perspective, IRT-PAP should be included as an alternative when deciding on the screening strategy in the implementation of CFNBS.

<http://dx.doi.org/10.1111/resp.70092>

## See also

Respirology. 2025 Jul 27. doi: 10.1111/resp.70092.

## Keywords

Neonatal Screening; Newborn; non pharmacological intervention - diagn; screening; diagnostic procedures;